Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
2001 2
2002 1
2003 3
2004 3
2005 1
2006 2
2007 3
2009 5
2010 5
2011 5
2012 7
2013 9
2014 10
2015 7
2016 4
2017 2
2018 5
2019 1
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

68 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for piris a
Search for Pipis A instead (3 results)
Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC. Rambow F, et al. Among authors: piris a. Cell. 2018 Aug 9;174(4):843-855.e19. doi: 10.1016/j.cell.2018.06.025. Epub 2018 Jul 12. Cell. 2018. PMID: 30017245 Free article.
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA. Jenkins RW, et al. Among authors: piris a. Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3. Cancer Discov. 2018. PMID: 29101162 Free PMC article.
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA. Frederick DT, et al. Among authors: piris a. Clin Cancer Res. 2013 Mar 1;19(5):1225-31. doi: 10.1158/1078-0432.CCR-12-1630. Epub 2013 Jan 10. Clin Cancer Res. 2013. PMID: 23307859 Free PMC article.
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA. Konieczkowski DJ, et al. Among authors: piris a. Cancer Discov. 2014 Jul;4(7):816-27. doi: 10.1158/2159-8290.CD-13-0424. Epub 2014 Apr 25. Cancer Discov. 2014. PMID: 24771846 Free PMC article.
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. Corcoran RB, et al. Among authors: piris a. Cancer Discov. 2012 Mar;2(3):227-35. doi: 10.1158/2159-8290.CD-11-0341. Epub 2012 Jan 16. Cancer Discov. 2012. PMID: 22448344 Free PMC article.
Continuous Spatial Sequences of Lichen Sclerosus, Penile Intraepithelial Neoplasia, and Invasive Carcinomas: A Study of 109 Cases.
Cañete-Portillo S, Sanchez DF, Fernández-Nestosa MJ, Piris A, Zarza P, Oneto S, Gonzalez Stark L, Lezcano C, Ayala G, Rodriguez I, Hoang MP, Mihm MC, Cubilla AL. Cañete-Portillo S, et al. Among authors: piris a. Int J Surg Pathol. 2019 Aug;27(5):477-482. doi: 10.1177/1066896918820960. Epub 2019 Jan 7. Int J Surg Pathol. 2019. PMID: 30614356
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.
Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. Mooradian MJ, et al. Among authors: piris a. Oncoimmunology. 2018 Feb 1;7(5):e1423172. doi: 10.1080/2162402X.2017.1423172. eCollection 2018. Oncoimmunology. 2018. PMID: 29721378 Free PMC article.
Rhabdomyosarcoma arising in a giant congenital melanocytic nevus.
Christman MP, Kerner JK, Cheng C, Piris A, Nepo AG, Sepehr A, Kroshinsky D. Christman MP, et al. Among authors: piris a. Pediatr Dermatol. 2014 Sep-Oct;31(5):584-7. doi: 10.1111/pde.12359. Epub 2014 Jun 9. Pediatr Dermatol. 2014. PMID: 24913904
Lethal melanoma in children: a clinicopathological study of 12 cases.
Prieto-Granada CN, Lezcano C, Scolyer RA, Mihm MC Jr, Piris A. Prieto-Granada CN, et al. Among authors: piris a. Pathology. 2016 Dec;48(7):705-711. doi: 10.1016/j.pathol.2016.08.008. Epub 2016 Oct 27. Pathology. 2016. PMID: 27956274
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, Fisher DE. Friedman AA, et al. Among authors: piris a. PLoS One. 2015 Oct 13;10(10):e0140310. doi: 10.1371/journal.pone.0140310. eCollection 2015. PLoS One. 2015. PMID: 26461489 Free PMC article.
68 results
Jump to page
Feedback